𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety and efficacy of donepezil in a 12-week, open-label trial in African Americans with mild to moderate Alzheimer’s disease

✍ Scribed by Patrick Griffith; Peter Lichtenberg; Robert Goldman; Lynn Burger; June Lato; Jennifer Payne-Parrish; Sharon Richardson

Book ID
118461892
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
61 KB
Volume
1
Category
Article
ISSN
1552-5260

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multinational, randomised, 12-week stu
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Efficacy and safety of donepezil over 3
Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease
✍ A. Burns; S. Gauthier; C. Perdomo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB 👁 2 views

## Abstract ## Objective This 132‐week, open‐label extension study assessed the long‐term efficacy and safety of donepezil in 579 patients with mild to moderate Alzheimer's disease (AD) who had previously participated in a 24‐week double‐blind study of 5 or 10 mg/day donepezil __vs__ placebo. ##